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combinations of inhaled corticosteroids and
long-acting b2-agonists in obstructive lung diseases: a
population-based, observational study
U. S. Bj€ornsdottir,1 S. T. Sigurðardottir,1,2 J. S. Jonsson,3,4 M. Jonsson,5 G. Telg,6 M. Thuresson,7
I. Naya,8 S. Gizurarson9
SUMMARY
Background: In 2010, the Icelandic government introduced a new cost-saving
policy that limited reimbursement of fixed inhaled corticosteroid/long-acting
b2-agonist (ICS/LABA) combinations. Methods: This population-based, retrospec-
tive, observational study assessed the effects of this policy change by linking spe-
cialist/primary care medical records with data from the Icelandic Pharmaceutical
Database. The policy change took effect on 1 January 2010 (index date); data for
the year preceding and following this date were analysed in 8241 patients with
controlled/partly controlled asthma and/or chronic obstructive pulmonary disease
(COPD) who had been dispensed an ICS/LABA during 2009. Oral corticosteroid
(OCS) and short-acting b2-agonist (SABA) use, and healthcare visits, were assessed
pre- and post-index. Results: The ICS/LABA reimbursement policy change led to
47.8% fewer fixed ICS/LABA combinations being dispensed during the post-index
period among patients whose asthma and/or COPD was controlled/partly con-
trolled during the pre-index period. Fewer ICS monocomponents were also dis-
pensed. A total of 48.6% of patients were no longer receiving any respiratory
medications after the policy change. This was associated with reduced disease
control, as demonstrated by more healthcare visits (44.0%), and more OCS
(76.3%) and SABA (51.2%) dispensations. Conclusions: Overall, these findings
demonstrate that changes in healthcare policy and medication reimbursement can
directly impact medication use and, consequently, clinical outcomes and should,
therefore, be made cautiously.
What’s known
Changes in reimbursement policies that require
patients to contribute a large amount towards the
cost of their medication can have a negative impact
on disease control. The use of separate inhaled
corticosteroid (ICS) and long-acting b2-agonist
(LABA) inhalers results in reduced asthma control,
compared with the use of a fixed ICS/LABA
combination. In addition, non-consensual inhaler
switches have been linked to reduced disease control
in patients with previously controlled asthma.
What’s new
Following changes in respiratory medication
reimbursement policy in Iceland, fewer fixed ICS/
LABA combinations were used by patients with
previously controlled/partly controlled asthma and/or
chronic obstructive pulmonary disease. Fewer ICS
monocomponents were dispensed, and patients used
more oral corticosteroids and short-acting b2-
agonists. This suggests that the policy change was
associated with poorer disease control.
Background
Fixed inhaled corticosteroid/long-acting b2-agonist
(ICS/LABA) combination therapy is well documented
in both asthma (1) and chronic obstructive pulmonary
disease (COPD) (2) management guidelines to achieve
and maintain control of symptoms, and reduce the
risk of exacerbations. Randomised controlled trials in
patients with controlled asthma show that discontinu-
ing a fixed ICS/LABA combination in favour of ICS
monotherapy results in a greater loss of asthma con-
trol compared with reducing the dose of the existing
fixed ICS/LABA combination (3). Use of ICS and
LABA monocomponents is associated with a higher
risk of exacerbations and higher reliever use than
fixed ICS/LABA combinations via a single inhaler (4).
Non-consensual inhaler switches in patients with con-
trolled asthma have been linked with reduced disease
control (5–7). Finally, using LABA monotherapy with-
out a concurrent ICS leads to poorer outcomes in
asthma and is associated with increased mortality;
therefore, the use of separate inhalers should be
avoided to prevent use of LABA monotherapy (8,9).
Among patients with COPD, several studies have
shown that the use of a fixed ICS/LABA combination
is more effective at controlling COPD than ICS or
LABA monotherapy (10–14). However, to our know-
ledge, the effects of non-consensual therapy switching
on COPD control have not been studied.
In September 2008, the Icelandic national eco-
nomy faced an unprecedented level of financial crisis,
with the possibility of national bankruptcy (15). One
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step taken by the Icelandic government to ensure
economic survival was to place restrictions on vari-
ous aspects of healthcare, including the use of spe-
cific medications, procedures and specialist care
across a number of therapeutic areas – a cost-con-
tainment step that has been used in other European
countries as a means of reducing expenditure (16).
Particularly, on 1 January 2010, the Icelandic Minis-
try of Health introduced a new regulation regarding
the reimbursement of fixed ICS/LABA combinations
related to any diagnosis. This change in the regula-
tion immediately moved the cost of continued the-
rapy with fixed ICS/LABA combinations to the
patient (unless a special reimbursement of the medi-
cation cost was applied for and approved) or forced
physicians and patients to find alternative regimens
and/or treatment strategies, such as receiving the two
medications via separate inhalers.
Changes in reimbursement policies that require
patients to contribute a large amount towards the
cost of their medication may result in a negative
impact on overall adherence (17,18), as has been
shown for asthma medications (19,20). In addition,
the use of separate ICS and LABA inhalers results in
reduced asthma control, compared with the use of a
fixed ICS/LABA combination (4). The same is true
when asthma patients change from a fixed ICS/LABA
combination to ICS monotherapy (3,21).
Ascertaining whether the revised reimbursement
policy in Iceland led to changes in medication use,
loss of disease control or an increased risk of exacer-
bations in patients with asthma and COPD is of cli-
nical interest. The current observational study
investigated the impact of the policy change on me-
dication and healthcare utilisation in patients diag-
nosed with asthma and/or COPD that was previously
controlled/partly controlled. Patients with uncon-
trolled disease were excluded from this analysis as
changes in medication use among these patients were




This was a population-based, retrospective, observa-
tional, registry study (NCT01369810). The study was
approved by the Icelandic Bioethics Committee (re-
ference VSNb2010110021), the Icelandic Data Protec-
tion Committee (reference 2011030368), the
Bioethics Committee of the Landspitali University
Hospital (reference 16 ÞH/ei) and the Icelandic
Directorate of Health (reference 2010110080).
Data were collected from both medical records
and the Icelandic Pharmaceutical Database. Data
derived from medical records included: date of birth;
gender; diagnoses [International Classification of Dis-
eases, 10th Edition, Clinical Modification (ICD-10-
CM) codes]; and number of healthcare contacts. The
pharmaceutical database provided data on: date of
birth; gender; dispensed drugs; drug name; drug
strength; number of doses; number of defined daily
doses (the assumed average maintenance dose per
day for a drug used for its main indication in
adults); and date of collection.
The linking of data from patient medical records
and the Icelandic Pharmaceutical Database was per-
formed by the Icelandic Directorate of Health. The
linked database is held by the Faculty of Pharmaceu-
tical Sciences, University of Iceland, Reykjavik,
Iceland.
The index date was 1 January 2010 (the date of
the reimbursement changes); data for this study were
collected from 1 January 2009 to 31 December 2010.
Patient population
Data were collected for all patients in the Icelandic
Pharmaceutical Database (N = 46,269) who had been
dispensed at least one fixed ICS/LABA combination
at any time during 2009. Patients were classified as
having controlled/partly controlled disease if they
had been dispensed ≤ 1 oral corticosteroid (OCS)
course and ≤ 2 short-acting b2-agonists (SABAs)
during 2009. Patients exceeding these limits were
considered to be uncontrolled and were excluded
from the analysis; patients who did not have a diag-
nosis of either asthma and/or COPD were also
excluded.
Outcome measures
The impact of the reimbursement policy change on
controlled/partly controlled patients was assessed
using the following outcomes: number of fixed ICS/
LABA combinations, ICS, LABAs, OCS and SABAs
dispensed pre- and post-index; and number of
healthcare visits for any reason (visits to general
practitioners, pulmonary specialists and allergists/
asthma specialists; data for private care visits were
not available) in the 1-year period before and after
the index date. Visits or admissions to hospitals were
not possible to extract in this study. To assess the
impact of the volcanic ash cloud that affected Iceland
in April 2010 on medication use and healthcare vi-
sits, we performed a sensitivity analysis in which
these outcomes were also assessed for a 3-month per-
iod (August–October) during 2009 and 2010.
The medication possession ratio [MPR; i.e. (num-
ber of dispensed defined daily doses/365) 9 100]
was used to determine the use of fixed ICS/LABA
combinations in the pre-index period (i.e. in 2009).
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lectures and involvement in
clinical research.
The MPR was used to categorise patients as follows:
continuous users (≥ 80%); intermediate users (40–
80%); occasional users (< 40%). Patients were also
stratified according to age: adolescents/children (aged
< 18 years), adults (aged 18–65 years) or elderly
patients (aged ≥ 65 years).
Statistical analyses
The main statistical analyses for this study were
descriptive, for which data are presented using stan-
dard summary statistics such as mean (with standard
deviation) and frequency (%). The risk of stopping
fixed-combination ICS/LABA treatment and of having
uncontrolled disease during the post-index period
(2010) was analysed using a logistic regression analysis;
the independent factors in the model were diagnosis
(asthma and/or COPD), age and gender. The results
are presented as odds ratios with corresponding 95%
confidence limits and p-values. The statistical analyses
were performed using R version 2.14.1 (R Foundation
for Statistical Computing, Vienna, Austria).
Results
Patients
From the database of 46,269 individuals,
13,814 patients received a fixed ICS/LABA combina-
tion during 2009. Of these, 1895 (13.7%) were
uncontrolled based on our predefined criteria
(dispensed > 1 OCS course and > 2 SABAs during
2009) and were, therefore, excluded. In addition,
another 3678 patients were excluded because they
had not been diagnosed with either asthma or
COPD. The remaining 8241 patients were considered
to be controlled/partly controlled (mean age,
47.0 years; 58.4% females) and were included in the
analysis (Figure 1). The majority of the controlled/
partly controlled patients had a diagnosis of asthma
(n = 6142; 74.5%), 1340 (16.3%) patients had
COPD, while 759 (9.2%) had a diagnosis of both
asthma and COPD (Table 1).
Prior to the index date, the majority of patients
were considered to be occasional users of fixed ICS/
LABA combinations (62.0%; n = 5111), while 25.9%
(n = 2134) were intermediate users and 12.1%
(n = 996) were continuous users. Mean age was
highest among continuous users and lowest among
occasional users. Similarly, continuous users had
more healthcare visits and asthma- and COPD-
related healthcare visits, compared with occasional or
intermediate users (Table 2). In addition, occasional
users were more likely to be OCS free during the
pre-index period than continuous or intermediate
users of fixed ICS/LABA combinations.
Medication use
The total use of respiratory medications 6 months
after the index date was 51.4% (Figure 2). A total of
48.6% of the patients who were controlled/partly
controlled prior to index were not dispensed any
respiratory medications during the post-index period:
54.0% of patients with asthma, 27.0% of those with
diagnoses of both asthma and COPD, and 35.7% of
those with COPD.
Overall, there were 47.8% fewer fixed ICS/LABA
combinations dispensed after the index date (mean
change from 197.5 to 103.1 fixed ICS/LABAs dis-
pensed per 100 patient-years); this included 34.4%
fewer ICS/LABA combinations dispensed in continu-
ous users (from 450.9 to 296.0 per 100 patient-
years), 39.8% fewer in intermediate users (from
254.2 to 153.0 per 100 patient-years) and 64.1%
fewer in occasional users (from 124.4 to 44.7 per
100 patient-years; Figure 3A). There were 68.0%
fewer dispensed ICS monocomponents (from 127.9
to 40.9 per 100 patient-years), although more LABA
monocomponents were dispensed (611.8%; from 1.7
to 12.1 per 100 patient-years).
Figure 1 Patient flow. COPD, chronic obstructive pulmonary disease; ICS/LABA, inhaled corticosteroid/long-acting
b2-agonist; OCS, oral corticosteroid; SABA, short-acting b2-agonist
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Occasional and intermediate users of fixed ICS/
LABA combinations and adolescents/children were
significantly more likely to discontinue ICS/LABA
combination therapy during the post-index period
(all p < 0.001 vs. continuous users and adult
patients, respectively; Table 3). Elderly patients and
those with a COPD or asthma/COPD diagnosis were
significantly more likely to continue fixed ICS/LABA
treatment post-index than adult patients and those
with an asthma diagnosis only, respectively (all
p < 0.001). The same factors were predictive of
having uncontrolled disease during the post-index
period (all p ≤ 0.001; Table 4).
Measures of disease control
More OCS and SABAs were dispensed during the
post-index period, compared with pre-index (Fi-
gure 3B and C). In the overall patient population,
there were 76.3% more OCS and 51.2% more SABAs
dispensed (from 16.0 to 28.2 and from 37.5 to
Table 1 Patient baseline and demographical characteristics and medication use (by disease type) in the pre-index










Males, n (%) 2574 (41.9) 261 (34.4) 594 (44.3) 3429 (41.6)
Mean age, years (SD) 39.8 (23.0) 65.6 (14.7) 69.6 (11.8) 47.0 (24.3)
SABAs dispensed, rate per patient-year 0.4 (0.6) 0.5 (0.7) 0.3 (0.6) 0.4 (0.6)
SABA-free patients, n (%) 4255 (69.3) 491 (64.7) 1058 (79.0) 5804 (70.4)
OCS dispensed, rate per patient-year 0.1 (0.3) 0.3 (0.5) 0.2 (0.4) 0.2 (0.4)
OCS-free patients, n (%) 5359 (87.3) 527 (69.4) 1037 (77.4) 6923 (84.0)
Dispensed medications, n (%)
LAMAs 0 (0.0)* 232 (30.6) 489 (36.5) 721 (8.7)
LTRAs 251 (4.1) 44 (5.8) 13 (1.0) 308 (3.7)
Antibiotics 783 (12.8) 232 (30.6) 303 (22.6) 1318 (16.0)
Theophylline 11 (0.2) 15 (2.0) 16 (1.2) 42 (0.5)
ICS monotherapy 263 (4.3) 33 (4.4) 23 (1.7) 319 (3.9)
LABA monotherapy 42 (0.7) 18 (2.4) 20 (1.5) 80 (1.0)
All healthcare care visits, per patient-year† 1.0 (1.3) 2.5 (2.9) 1.9 (2.6) 1.3 (1.9)
Asthma- and COPD-related healthcare visits, per
patient-year†
0.6 (1.1) 1.5 (2.2) 1.1 (1.9) 0.8 (1.4)
Each dispensation was assumed to account for a 3-month supply of reliever or maintenance medication. COPD, chronic obstructive
pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting b2-agonist; LAMA, long-acting muscarinic antagonist; LTRA,
leukotriene-receptor antagonist; OCS, oral corticosteroid; SABA, short-acting
b2-agonist; SD, standard deviation. *As per definition, any use of LAMA classifies the patient as having COPD.
†Visits to general
practitioners, pulmonary specialists and allergists/asthma specialists (excludes hospital visits/admissions).
Table 2 Patient baseline and demographical characteristics and medication use for occasional, intermediate and










Males, n (%) 2136 (41.8) 877 (41.1) 416 (41.8) 3429 (41.6)
Age, years 41.8 (24.2) 53.5 (22.9) 59.9 (18.7) 47.0 (24.3)
SABAs dispensed, rate per patient-year 0.4 (0.6) 0.4 (0.7) 0.4 (0.7) 0.4 (0.6)
OCS dispensed, rate per patient-year 0.1 (0.3) 0.2 (0.4) 0.3 (0.4) 0.2 (0.4)
Asthma- and COPD-related healthcare visits,
per patient-year*
0.6 (1.1) 1.1 (1.6) 1.5 (2.0) 0.8 (1.4)
Values presented as mean (SD), unless otherwise stated. Each dispensation was assumed to account for a 3-month supply of reliever
or maintenance medication. COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting b2-agonist;
OCS, oral corticosteroid; SABA, short-acting b2-agonist; SD, standard deviation. *Visits to general practitioners, pulmonary specialists
and allergists/asthma specialists (excludes hospital visits/admissions).
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56.7 dispensations per 100 patient-years, respectively).
The same pattern was seen in the continuous,
intermediate and occasional users subgroups for the
number of OCS dispensations [ranging from 64.3%
(from 12.6 to 20.7 per 100 patient-years) to 88.8%
more dispensations (from 25.9 to 48.9 per
100 patient-years)] and SABA dispensations [ranging
from 38.7% (from 35.4 to 49.1 per 100 patient-years)
Figure 2 Drugs collected during the first 6 months following the index date (1 January 2010). R03 class medications are
defined as ‘Drugs for obstructive airway diseases’. COPD, chronic obstructive pulmonary disease; ICS, inhaled
corticosteroid; LABA, long-acting b2-agonist; SABA, short-acting b2-agonist
Figure 3 Comparison between medications dispensed [fixed ICS/LABA combinations (A), OCS (B) and SABAs (C)] and
healthcare visits (for any reason) (D) per 100 patient-years in the pre- (2009) and post-index (2010) period in continuous,
intermediate and occasional users and in all patients combined. Error bars represent 95% confidence intervals.
ICS/LABA, inhaled corticosteroid/long-acting b2-agonist; OCS, oral corticosteroid; SABA, short-acting b2-agonist
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to 85.7% more dispensations (from 42.0 to 78.0 per
100 patient-years)]. The change was greatest in the
continuous users subgroup for both OCS (88.8%)
and SABAs (85.7%) dispensed.
Healthcare visits (for any reason)
During the post-index period, there were 44.0%
more total healthcare visits (from 79.8 to 114.9 visits
per 100 patient-years) in the overall patient popula-
tion (Figure 3D); this change was particularly high
in the occasional users subgroup (71.0%; from 54.8
to 93.7 visits per 100 patient-years).
Sensitivity analysis
Healthcare utilisation in August–October of the pre-
and post-index periods was assessed to exclude the
potential confounding effect of the volcanic ash
cloud that affected Iceland during April 2010. In
these analyses, data for the pre- and post-index peri-
ods regarding the number of fixed ICS/LABAs, OCS
and SABAs dispensed were similar to those obtained
for the whole study period: overall, there were 49.7%
fewer fixed ICS/LABAs dispensed (from 51.5 to
25.9 dispensations per 100 patient-years); in the
occasional users subgroup, there were 69.0% fewer
fixed ICS/LABA dispensations (from 34.8 to 10.8 per
100 patient-years). In the total population, there
were 75.6% more OCS dispensed (from 4.1 to
7.2 dispensations per 100 patient-years) and 41.4%
more SABA dispensations (from 9.9 to 14.0 per
100 patient-years) during the post-index, vs. the pre-
index, period.
By contrast, the volcanic ash cloud may have
impacted healthcare visits, as somewhat different
findings were observed when data for August–Octo-
ber of the pre- and post-index periods were com-
pared. Overall, there were 10.9% fewer healthcare
visits (from 29.3 to 26.1 visits per 100 patient-years);
this was primarily driven by the fact that there were
27.7% fewer healthcare visits in the occasional users
subgroup (from 25.3 to 18.3 visits per 100 patient-
years). More healthcare visits were seen in continu-
ous and intermediate users (16.1%, from 40.9 to
47.5 visits per 100 patient-years and 3.9%, from
33.6 to 34.9 visits per 100 patient-years, respectively).
Discussion
This population-based, retrospective, observational
study shows that the Icelandic government’s policy
change regarding respiratory medications, whereby
reimbursement of fixed ICS/LABA combinations was
limited, resulted in fewer dispensations of fixed ICS/
LABA combinations. While somewhat more LABA
monotherapies were also dispensed, this change was
not large enough to compensate for the lower ICS/
LABA use, and fewer ICS monotherapies were dis-
pensed. Notably, a marked proportion of patients
with asthma and/or COPD were no longer receiving
any respiratory medications at all. Deterioration in
disease control was observed following the policy
change, as demonstrated by more OCS and SABA
dispensations and more healthcare visits.
Occasional users, the patient subgroup who had
the fewest fixed ICS/LABA combinations dispensed
before the index date, were the least likely to receive
Table 3 Patient characteristics associated with a change
in the risk of not receiving previously prescribed fixed
ICS/LABA combination therapy (Yes/No) post-index
(during 2010) as a dependent variable
Characteristic OR (95% CL) p-value
Diagnosis of asthma and
COPD*
0.45 (0.37, 0.54) < 0.001
Diagnosis of COPD* 0.76 (0.65, 0.88) < 0.001
Adolescent/child† 1.54 (1.33, 1.79) < 0.001
Elderly† 0.69 (0.61, 0.78) < 0.001
Men‡ 1.03 (0.93, 1.15) 0.517
Occasional users§ 12.88 (10.73, 15.55) < 0.001
Intermediate users§ 2.72 (2.25, 3.32) < 0.001
CL, confidence limit; COPD, chronic obstructive pulmonary
disease; ICS/LABA, inhaled corticosteroid/long-acting b2-
agonist; OR, odds ratio. *vs. an asthma only diagnosis. †vs.
adult patients (aged 18–65 years). ‡vs. female patients.
§vs. continuous users. OR values > 1.00 and < 1.00 indicate
an increased or decreased risk, respectively, of discontinuing
fixed ICS/LABA therapy.
Table 4 Patient characteristics associated with a change
in the risk of having uncontrolled disease during the
post-index period (2010)
Characteristic OR (95% CL) p-value
Diagnosis of asthma and
COPD*
2.32 (1.87, 2.87) < 0.001
Diagnosis of COPD* 1.42 (1.16, 1.73) 0.001
Adolescent/child† 0.47 (0.34, 0.63) < 0.001
Elderly† 1.47 (1.24, 1.74) < 0.001
Men‡ 0.96 (0.82, 1.12) 0.603
Occasional users§ 0.50 (0.41, 0.61) < 0.001
Intermediate users§ 0.75 (0.61, 0.93) 0.008
CL, confidence limit; COPD, chronic obstructive pulmonary
disease; OR, odds ratio. *vs. an asthma only diagnosis.
†vs. adult patients (aged 18–65 years). ‡vs. female patients.
§vs. continuous users. OR values > 1.00 and < 1.00 indicate
an increased or decreased risk, respectively, of having
uncontrolled disease.
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these medications after the reimbursement change,
which may, in part, have been because of an unwill-
ingness to pay for their own medication. These
patients were, on average, younger than intermediate
or continuous users, and were most likely to be OCS
free during the pre-index period. The patients most
likely to receive ICS/LABA treatment post-index were
the continuous users, suggesting that physicians and
healthcare providers exercised good judgement by
concentrating the use of this class of drug in patients
likely to have the greatest need for the fixed combi-
nation. Nonetheless, although continuous users had
a smaller relative reduction in fixed ICS/LABA com-
bination use, compared with occasional and interme-
diate users, they had a greater increase in OCS and
SABA use, showing the greatest loss of disease con-
trol. This increase was apparent despite higher base-
line OCS and, to a certain extent, SABA use in the
continuous than occasional users of ICS/LABA and,
therefore, suggests that these changes are not
explained by potential regression to the mean, but
perhaps that continuous-use patients had the highest
level of underlying disease activity. In addition, the
occasional users had the greatest relative increase in
healthcare visits, an effect that may stem from a lack
of preparation regarding the switch of medication.
However, these visits could be because of a number
of reasons, and may not have been in response to
respiratory symptoms.
It is particularly worrisome that 27–54% of
patients diagnosed with asthma, COPD or both were
no longer receiving any respiratory medications at all
during the post-index period, as this will inevitably
lead to loss of disease control, especially in patients
with COPD. This suggests that there are inconsisten-
cies between recommended disease management and
actual clinical practice, an observation that has been
noted elsewhere (22,23).
Our results are similar to those observed following
changes to the reimbursement schedule for cardiovas-
cular medications implemented by the Icelandic Min-
istry of Health in 2009. Specifically, changes in the
reimbursement policy for statins were associated with
increases in cholesterol levels in patients with hyper-
lipidaemia and heart disease (24). Other studies in
the setting of asthma and COPD have drawn similar
conclusions to ours (19,20). A study in children with
asthma in the USA found that an increase in out-of-
pocket medication costs led to a reduction in
adjusted medication use and increased asthma-related
hospitalisations in children (19). In Canada, a signifi-
cant reduction in the use of inhaled medications was
seen following the implementation of cost-sharing
policies, mostly because of a reduction in treatment
initiation and greater treatment discontinuation (20).
The results of this study raise the question of
whether any reimbursement reductions made by the
government with the intent to save cost are partially
or completely offset by increases in other healthcare
resource use. There was more OCS and SABA use, as
well as more healthcare visits, after the reimburse-
ment change. A complete assessment of the health-
economic and financial consequences of this change
in reimbursement policy was beyond the scope of
this study.
A strength of this study is that it was performed in
a large group of patients without any restrictions in
factors such as age, employment status, concomitant
medications and comorbidities or healthcare insur-
ance. Observational studies using clinical databases
enable outcomes to be assessed in a real-life, non-in-
terventional, naturalistic setting (25). As a result, the
management, prescribing patterns and adherence to
guidelines in clinical practice may be effectively stud-
ied and characterised. However, such a construct is
not without its weaknesses; as with all database stu-
dies, data retrieval is limited to the variables included
in the databases, and potential unknown confounding
factors may still reside in the data. In addition, the
fact that patients with uncontrolled asthma or COPD
were excluded from this analysis could have led to an
overestimation of the effect of the reimbursement
change. However, it was necessary to exclude these
patients as they were more likely to switch medica-
tions because of medical reasons than patients with
controlled/partly controlled disease.
A significant environmental change that coincided
with the study period was the volcanic eruption in
Iceland and subsequent ash cloud that may have
confounded the results. It is not known whether the
ash particles in the atmosphere had an effect on
respiratory conditions or influenced the availability
of, or access to, healthcare resources (e.g. because of
disruptions in travel). We controlled for this poten-
tial confounding factor by assessing data from a 3-
month period during 2009 and a 3-month period in
2010 during which the ash cloud had dissipated
(August–October); the results of this sensitivity
analysis indicated that the volcanic ash cloud did not
markedly influence the full 12-month outcomes.
In this study, the validity of the asthma and
COPD diagnoses could not be verified, and the study
was limited by the inability to perform further evalu-
ations involving more detailed clinical characteristics
of the patients (e.g. hospital data and categorisation
by disease severity or lung function measurements).
Such further evaluation would have permitted more
detailed examination of the relationship between
poor compliance and disease outcomes; however, it
was beyond the scope of the current analysis to sub-
ª 2014 The Authors. International Journal of Clinical Practice Published by John Wiley & Sons Ltd.
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divide the continuous users group into balanced sub-
groups by severity to quantify if the degree of change
in continuous use correlated with the degree of dete-
rioration in disease activity. In addition, it was not
known if some patients had non-eosinophilic
asthma. As the role of ICS therapies in these patients
is controversial, the presence of patients with non-
eosinophilic asthma could have had an impact on
the results of this analysis (26,27).
In conclusion, among patients with previously
controlled/partly controlled asthma and/or COPD in
Iceland, the use of fixed ICS/LABA combinations was
lower following a reimbursement policy change, but
the use of ICS and LABA monotherapy was not
comparably higher. There were, however, more OCS
and SABAs dispensed and more healthcare visits,
suggesting decreased disease control. The results of
this study indicate that changes to healthcare policy
and medication reimbursement should be made cau-
tiously, since they can lead to unintended clinical
consequences. The Icelandic Ministry of Health has
now reversed this reimbursement policy change.
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